Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease

The gene encoding apolipoprotein E (APOE) on chromosome 19 is the only confirmed susceptibility locus for late-onset Alzheimer's disease. To identify other risk loci, we conducted a large genome-wide association study of 2,032 individuals from France with Alzheimer's disease (cases) and 5,328 controls. Markers outside APOE with suggestive evidence of association (P < 10−5) were examined in collections from Belgium, Finland, Italy and Spain totaling 3,978 Alzheimer's disease cases and 3,297 controls. Two loci gave replicated evidence of association: one within CLU (also called APOJ), encoding clusterin or apolipoprotein J, on chromosome 8 (rs11136000, OR = 0.86, 95% CI 0.81–0.90, P = 7.5 × 10−9 for combined data) and the other within CR1, encoding the complement component (3b/4b) receptor 1, on chromosome 1 (rs6656401, OR = 1.21, 95% CI 1.14–1.29, P = 3.7 × 10−9 for combined data). Previous biological studies support roles of CLU and CR1 in the clearance of β amyloid (Aβ) peptide, the principal constituent of amyloid plaques, which are one of the major brain lesions of individuals with Alzheimer's disease.

[1]  N. Breslow,et al.  Estimation of multiple relative risk functions in matched case-control studies. , 1978, American journal of epidemiology.

[2]  G. Vega,et al.  Apolipoproteins in human cerebrospinal fluid. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[3]  V. Nussenzweig,et al.  Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus , 1982, The Journal of experimental medicine.

[4]  Steven A. Johnson,et al.  Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat , 1990, Neuron.

[5]  C. Finch,et al.  Sulfated glycoprotein 2: new relationships of this multifunctional protein to neurodegeneration , 1992, Trends in Neurosciences.

[6]  T. Wisniewski,et al.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. , 1993, The Biochemical journal.

[7]  E. Matsubara,et al.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[9]  J. Rogers,et al.  Aggregation State‐Dependent Activation of the Classical Complement Pathway by the Amyloid β Peptide , 1997, Journal of neurochemistry.

[10]  B. Dubois,et al.  Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.

[11]  A. Fagan,et al.  Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. , 1999, The Journal of clinical investigation.

[12]  D. Galasko,et al.  Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. , 2000, Biochemical and biophysical research communications.

[13]  A Rostagno,et al.  Apolipoprotein J (clusterin) and Alzheimer's disease , 2000, Microscopy research and technique.

[14]  J. Lambris,et al.  Complement and innate immunity. , 2000, Immunopharmacology.

[15]  John D Lambris,et al.  Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[17]  Bruce J Aronow,et al.  Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Ashford,et al.  Non-familial Alzheimer's disease is mainly due to genetic factors. , 2002, Journal of Alzheimer's disease : JAD.

[19]  Bruce J Aronow,et al.  ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo , 2004, Neuron.

[20]  D-A Tregouet,et al.  Cox proportional hazards survival regression in haplotype-based association analysis using the Stochastic-EM algorithm , 2004, European Journal of Human Genetics.

[21]  D. Holtzman.  In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. , 2004, Journal of molecular neuroscience : MN.

[22]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[23]  Rena Li,et al.  Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes , 2006, Neurobiology of Aging.

[24]  L. Fratiglioni,et al.  Role of genes and environments for explaining Alzheimer disease. , 2006, Archives of general psychiatry.

[25]  Winnie S. Liang,et al.  GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. , 2007, Neuron.

[26]  D. Holtzman,et al.  Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[28]  Philippe Amouyel,et al.  Genetic heterogeneity of Alzheimer's disease: Complexity and advances , 2007, Psychoneuroendocrinology.

[29]  S. Heath,et al.  Investigation of the fine structure of European populations with applications to disease association studies , 2008, European Journal of Human Genetics.

[30]  Peter Donnelly,et al.  Progress and challenges in genome-wide association studies in humans , 2008, Nature.

[31]  B. Maher,et al.  The case of the missing heritability , 2008 .

[32]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[33]  B. Maher.  Personal genomes: The case of the missing heritability , 2008, Nature.

[34]  A. J. Slater,et al.  Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. , 2008, Archives of neurology.

[35]  Christoph Lange,et al.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. , 2008, American journal of human genetics.

[36]  Jun Zhou,et al.  Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s disease , 2008, Journal of neurochemistry.

[37]  Eden R Martin,et al.  Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. , 2009, American journal of human genetics.

[38]  M. Hamshere,et al.  Meta-analysis of linkage studies for Alzheimer's disease—A web resource , 2009, Neurobiology of Aging.

[39]  Ronald C. Petersen,et al.  Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease , 2009, Alzheimer's & Dementia.

[40]  R. Khera,et al.  Complement Receptor 1: Disease associations and therapeutic implications , 2008, Molecular Immunology.